Charles Morgan, Chairman
Charles Morgan is a resources and technology venture capitalist who has identified emerging sectors and acquired early stage and strategic positions in a wide range of ventures around the globe. He has a proven track record in identifying early stage commercial opportunities and acting as a corporate catalyst, acquiring strategic assets and positions, partnering with regional and technology experts, securing teams of appropriate executives and funds to build and develop projects and companies.
Mr Morgan started his career in futures broking in London with M.L. Doxford & Co and left to join merchant bank Morgan Grenfell Limited in Sydney, Australia before moving to broking with ANZ McCaughan Dyson Limited in Melbourne and London. He then joined BZW Securities Limited in London before going back to Australia to form Morgan McFarlane a licensed securities dealer which raised equity funds for (mainly) Perth based mining and oil exploration companies.
Mr Morgan is involved in investing in various businesses and start-ups in the UK and San Francisco including Neuro‐Bio Ltd (discoverer of cause and potential drugs for Alzheimer’s, Parkinson’s and Motor Neurone Disease), TGMatrix (shipper and transport matching engine), Brytlyt (GPU based data base analytics), PensionBee (gathering people’s various pensions into one), Teamable (social media based employment) and Headnote (de‐chequing legal firms in the US).
He is currently Chair of both Grand Gulf Energy Limited and Whitebark Energy Ltd.
Melissa Sturgess, Chief Executive Officer
Melissa Sturgess holds a BSc and an MBA and has more than 20 years of experience as a director of UK and Australian Stock Exchange quoted companies, mainly focused on the acquisition, structuring and financing of natural resources deals across Africa. Miss Sturgess commenced her listed company career as a member of the Executive Committee of Aquarius Platinum Limited, the most successful Australian/UK dual listed company and a miner of platinum in South Africa and Zimbabwe. She was also founding director of Sylvania Resources Limited and a number of other companies operating in the metals and mining sector throughout Africa and listed on the AIM Market in London. During her career Miss Sturgess has raised significant amounts of capital and in 2016 she spearheaded the £50m financing for the acquisition of a building materials business in the Channel Islands. After a short break, her interest in the cannabis sector commenced with a trip to Israel to review the medicinal cannabis research in that country. She subsequently founded UK based, NEX Exchange quoted Ananda Developments plc to invest in the sector. She is also the founder of premium, luxury CBD brand Montana (montanawellness.co).
Dr. Inbar Maymon Pomeranchik, PhD, Executive Director
Dr Pomeranchik holds a PhD in plant sciences molecular biology from the Hebrew University of Jerusalem and a multi-disciplinary post-doctorate from the Weizmann Institute, combining drug biochemistry with plant science. Inbar has hands-on experience in all aspects of the Biotech industry obtained through 15 years of molecular and genetic research and development: from academic research to commercial project lead, from small start-ups to large corporations. More recently, Dr Pomeranchik founded Biodiligence Limited, a private company, which provides consultancy services in the field of biotechnology and agricultural technology within the Medicinal Cannabis space for venture capitalists, private equity investors and family offices. Inbar is at the forefront of the scientific thinking regarding medical cannabis and is a well-respected figure in the global cannabis eco-system. She is regular speaker at cannabis conferences around the world.
John Treacy, Non-Executive Director
Mr Treacy is an experienced London-based small cap financier who specialises in working with growing companies. He qualified as a solicitor in the London office of a major international law firm where he specialised in Capital Markets and Mergers & Acquisitions. From there he moved on to practice corporate finance in the advisory teams of several prominent UK brokerages where he acted as an adviser to a number of AIM companies and advised on numerous IPOs, acquisitions, debt restructurings and placings.
Peter Redmond, Non-Executive Director
Peter is a corporate financier with over 30 years’ experience in corporate finance and venture capital. He has acted on and assisted a wide range of companies to attain a listing over many years on the Unlisted Securities Market, the Main Market of the London Stock Exchange and AIM, whether by IPO or in many cases via reverse takeovers, across a wide range of sectors, ranging from technology through financial services to natural resources and, in recent years has done so as a director of the companies concerned. He was a founder director of Cleeve Capital plc (now Satellite Solutions Worldwide Group plc) and Mithril Capital plc (now Be Heard Group plc), both listed on AIM, and took a leading role in the reconstruction and refinancing of AIM-quoted 3Legs Resources plc (now SalvaRx). Peter was also primarily responsible for the decision for the Company to invest in both SalvaRx and Eco. He is also a director of Hemogenyx plc (where he was involved in creating the precursor vehicle) and URA Holdings plc.